PHASE-II TRIAL OF TAXOL IN PATIENTS WITH ADENOCARCINOMA OF THE UPPER GASTROINTESTINAL-TRACT (UGIT) - THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP(ECOG) RESULTS

Taxol was administered as a 24-hour continuous infusion at 250 mg/m(2) in this Phase II trial in patients with adenocarcinomas of the upper gastrointestinal tract (UGIT). Twenty-five patients were entered betwe en July 1991 and June 1992, twenty-three were eligible and were evalua ted for toxicity and twenty-two were assessable for response. There wa s one partial response (4.5%) in a patient with liver metastases, with a duration of 6 months. Toxicity was primarily neutropenia. Taxol as a single agent appears to have little activity in adenocarcinoma of th e UGIT.